These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 28782665)

  • 1. Reply.
    Chhatwal J
    Clin Gastroenterol Hepatol; 2017 Nov; 15(11):1815. PubMed ID: 28782665
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial: hepatitis C direct acting antiviral agents and the kidney-authors' reply.
    Maan R; Feld JJ; Duarte-Rojo A
    Aliment Pharmacol Ther; 2017 Aug; 46(3):379-380. PubMed ID: 28677289
    [No Abstract]   [Full Text] [Related]  

  • 3. Societal Perspectives and Patient/Public Involvement in Direct-Acting Antiviral Agent Coverage of Hepatitis C Treatment in the United States.
    Liu X; Lee JL; Yoo JW
    Clin Gastroenterol Hepatol; 2017 Nov; 15(11):1814-1815. PubMed ID: 28606844
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments.
    Ohashi H; Koizumi Y; Fukano K; Wakita T; Perelson AS; Iwami S; Watashi K
    Proc Natl Acad Sci U S A; 2017 Jun; 114(23):E4527-E4529. PubMed ID: 28512226
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply.
    Wang C; Chen G; Lau G
    Clin Gastroenterol Hepatol; 2017 Apr; 15(4):605-606. PubMed ID: 28025157
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to: "Real-world data on antiviral treatments for hepatitis C virus infections: Can we define intention to treat or per protocol analyses?".
    Buggisch P; Zeuzem S
    J Hepatol; 2018 Aug; 69(2):553. PubMed ID: 29758332
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to: "Extended DAA indications for hepatitis C patients awaiting liver transplantation and further statistical considerations".
    Londoño MC; Forns X; Pascasio JM
    J Hepatol; 2018 Mar; 68(3):627-628. PubMed ID: 29080809
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply.
    Fernández Carrillo C; Perelló C; Calleja JL
    Clin Gastroenterol Hepatol; 2017 May; 15(5):791. PubMed ID: 28163213
    [No Abstract]   [Full Text] [Related]  

  • 9. The clinical importance of hepatitis C genotyping in the United States.
    O'Brien S
    MLO Med Lab Obs; 2013 Nov; 45(11):16-7. PubMed ID: 24313119
    [No Abstract]   [Full Text] [Related]  

  • 10. Editorial: are additional tests needed to predict sustained virologic response in hepatitis C treated with interferon-free direct-acting antiviral combinations? Authors' reply.
    Fourati S; Pawlotsky JM
    Aliment Pharmacol Ther; 2018 Mar; 47(6):849-850. PubMed ID: 29446133
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to: "High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: Results of the Irish Early Access Programme".
    Foster GR
    J Hepatol; 2016 Aug; 65(2):448. PubMed ID: 27132169
    [No Abstract]   [Full Text] [Related]  

  • 12. In brief: Hepatic injury with hepatitis C drugs.
    Med Lett Drugs Ther; 2015 Nov; 57(1481):156. PubMed ID: 26529136
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to the comment "infection with hepatitis C virus, interferon α and lupus: an odd association".
    Auñón P; Morales E
    Nefrologia; 2015; 35(5):507-8. PubMed ID: 26306965
    [No Abstract]   [Full Text] [Related]  

  • 14. Overcoming barriers to care for hepatitis C.
    Clark PJ; Muir AJ
    N Engl J Med; 2012 Jun; 366(26):2436-8. PubMed ID: 22738095
    [No Abstract]   [Full Text] [Related]  

  • 15. Hepatitis B Virus Infection and Hepatitis C Virus Treatment in a Large Cohort of Hepatitis C-Infected Patients in the United States.
    Moorman AC; Xing J; Rupp LB; Gordon SC; Spradling PR; Boscarino JA; Schmidt MA; Daida YG; Teshale EH; Holmberg SD;
    Gastroenterology; 2018 Feb; 154(3):754-758. PubMed ID: 29360428
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to Calcagno et al.
    Kieran JA; Schmitz S; O'Leary A; Walsh C; Bergin C; Norris S; Barry MG
    Clin Infect Dis; 2013 Jun; 56(11):1678-9. PubMed ID: 23418277
    [No Abstract]   [Full Text] [Related]  

  • 17. Adverse events raise concerns over safety of new hepatitis C drugs.
    McCarthy M
    BMJ; 2017 Jan; 356():j490. PubMed ID: 28137772
    [No Abstract]   [Full Text] [Related]  

  • 18. Sofosbuvir (Sovaldi) for hepatitis C virus.
    Lomberk M; Klibanov OM
    Nurse Pract; 2015 Sep; 40(9):16-9. PubMed ID: 26274882
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial: good news to patients with thalassaemia-HCV clearance made easy with direct acting antivirals. Authors' reply.
    Mangia A; Piazzolla V; Santoro R
    Aliment Pharmacol Ther; 2017 Sep; 46(6):629-630. PubMed ID: 28805326
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply to Harrington et al.
    Sidharthan S; Kohli A; Kottilil S
    Clin Infect Dis; 2015 Aug; 61(4):667-8. PubMed ID: 26002847
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.